BIS News and Press, ProShares UltraShort Nasdaq Biotechnology From 10/10/23

2023-10-10 07:16:00 ET Summary European countries have been plagued by a persistent medicine shortage for the past few years. Supply chain disruptions and increased demand are driving the shortfall. There are potential solutions; and one could involve breeding a whole lot more...

2023-09-29 23:45:00 ET Summary A combination of public and private investments in neuroscience, government grants, and charitable donations are helping accelerate a wave of advancements and opportunities in neuroscience. Recent clinical trial success for the second significant, di...

2023-06-21 13:40:13 ET UltraShort Nasdaq Biotechnology ( NASDAQ: BIS ) - $0.0214 . 30-Day SEC Yield of 0.81% as of May 31. Payable Jun 28; for shareholders of record Jun 22; ex-div Jun 21. For further details see: UltraShort Nasdaq Biotechnology declares quar...

Summary TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs. Headwinds and risks involved. Overview CytoDyn Inc. (CYDY) is a Vanc...

Summary Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock. However, the tori PDUFA is the major catalytic event here. It is interesting to see that despite its foray into original R&D through a Chine...

Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...

ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...

Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...

We are bearish on all American bear market ETFs. Measuring the purchase levels of short ETFs replaces the old, odd lot and total short selling indicators so popular in the 1960s, 70s and 80s. The level of buying of 31 short Proshare ETFs suggests the stock market is rising against...

After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpo...